Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Jan 20, 2015 6:04pm

249 Views

Post# 23341467

RE:RE:RE:RE:RE:RE:RE:Phase 3: New Valuation

Hi Tovinv

I agree with your analysis and perspective on rvx market value, but one only has to look at Esperion Therapeutics which has a current market cap of 800 million which went public last year who have major analysts thinking double valuation for a late phase drug to lower LDL. We may have a drug that has lowers mace by 30% to 50% potentially yet we have a market cap of 60 million. So there can be market discrepancies. By all accounts rvx valuation should be higher than Esperion yet it is not.

Do you not agree?

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects